esmo: first-line erlotinib improves nsclc outcomes
Published 13 years ago • 401 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
0:58
first line treatment options for activating egfr non-small cell lung cancer | dr. alexander spira
-
2:39
esmo 2020 highlights on 1st line lorlatinib for alk nsclc: the crown study
-
10:09
esmo 2020 expert video report on long term ici outcomes in lung cancer
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
9:58
esmo sweden 2008: benefits of customising erlotinib therapy for nsclc.
-
3:22
tigit combo delivers significant improvement in lung cancer treatment at esmo 2024
-
16:10
esmo 2024 - israel (izzy) lowy
-
1:06
lung cancer highlights from esmo 2022
-
0:36
esmo 2019 daily reporter - editor's picks: lung cancer
-
7:00
expert report on neoadjuvant immune checkpoint inhibitors for nsclc
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
2:57
esmo 2024 highlights in thoracic oncology: dr. molly li shares insights
-
24:07
esmo 2024 - day 1
-
2:48
changing course and improving dismal outcomes in lung cancer: 2022 esmo florida
-
19:34
70. esmo 2023 - small cell lung cancer
-
5:18
expert video report on amivantamab in combination therapy for 1l treatment in egfrm, advanced nsclc
-
18:29
esmo 2023 lung cancer - chapter 2 highlights – papillon, mariposa, mariposa-2, libretto-431